Simplex
Libat Weizman is an R&D Analyst at Simplex since September 2021, with prior experience as a Neuroscientist at the Champalimaud Foundation from September 2019 to December 2020 and at Tel Aviv Sourasky Medical Center from November 2017 to May 2019. At the Champalimaud Foundation, Libat Weizman conducted research on the neuropharmacological effects of psilocybin, focusing on its antidepressant mechanisms related to cortical excitability and cognitive flexibility. Academic credentials include a Master of Science in Neuroscience from Tel Aviv University and a Bachelor of Science in Life Science and Cognitive Science from The Hebrew University of Jerusalem.
Simplex
Fully regulated as a financial institution, Simplex processes credit card payments with a 100% fraud protection guarantee – in case of a fraud chargeback, the merchant gets paid by Simplex. Utilizing its cutting-edge fraud prevention solution and AI technology, Simplex blocks fraudulent users and allows legitimate users to complete payments,thereby, increasing conversion rates and enabling merchants to focus on their business growth. In today's banking echo-system Crypto-related businesses are underserved. Simplex enables personal individuals and businesses to get an EU IBAN account for their banking activity having all the necessary payment account functions